Clinical trials
Metastatic Head and Neck Squamous Cell Carcinoma clinical trials
Below are recruiting metastatic head and neck squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 223 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06494995RecruitingPhase 2
AK104 and low-dose radiation for advanced head and neck cancer
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06525220RecruitingPhase 3
New drug combo vs. standard for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
Mobile, AlabamaAges 18 years+ - NCT06532279RecruitingPhase 2
Testing BMX-001 with chemoradiation for head and neck cancer
This trial tests whether adding BMX-001 (a drug that may protect healthy tissues) to standard chemoradiation can reduce side effects and improve outcomes for people with head and neck cancer. It's a randomized study, so you would have a 50/50 chance of getting BMX-001 or a placebo.
Gilbert, ArizonaAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT06540443RecruitingPhase 1
Enhanced MRI for staging head and neck cancer
This trial tests a new imaging agent (MPB-2043) that may help doctors see cancer spread to lymph nodes more clearly during an MRI scan. It is for people with head and neck cancer who are planning to have lymph node surgery.
TaipeiAges 20 years+ - NCT06557889RecruitingPhase 2
Fewer chemo cycles with immunotherapy for head and neck cancer
This study tests whether giving fewer chemotherapy cycles combined with the immunotherapy drug pembrolizumab works as well as the standard full course of chemo plus pembrolizumab for head and neck cancer that has come back or spread. It is for people whose tumors have the PD-L1 protein.
AmiensAges 18 years+ - NCT06797986RecruitingPhase 1/Phase 2
Vaccine for HPV-positive head and neck cancer
This trial tests an investigational vaccine called BVAC-E6E7 for head and neck cancer caused by HPV types 16 or 18 that has come back or spread. It is for people who have already tried standard treatments like platinum chemo or immunotherapy, or can't take them.
SeoulAges 19 years+ - NCT06601335RecruitingPhase 3
New immunotherapy combo for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
Wuhan, HubeiAges 18–75 - NCT06607406Recruiting
Timing of radiation after surgery for head and neck cancer
This study tests whether starting radiation therapy more than 6 weeks (but within 16 weeks) after surgery is safe and effective for people with certain high-risk head and neck cancers. It could help those who had to delay radiation for recovery or other reasons.
Charlotte, North CarolinaAges 18 years+ - NCT06636734RecruitingPhase 2
Lovastatin plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.
Atlanta, GeorgiaAges 18 years+ - NCT06639191RecruitingEarly Phase 1
Study of a new drug for cancers expressing CD44v6
This trial tests a new radioactive drug called [177Lu]Lu-AKIR001 for patients with certain advanced cancers (like thyroid, head and neck, lung, vulvar, or cervical cancer) that have a specific protein called CD44v6 on their surface. The goal is to see if this treatment can help when standard options have stopped working.
Stockholm, Stockholm CountyAges 18 years+ - NCT06668961RecruitingPhase 2
New combo therapy for head and neck cancer that has returned or spread
This trial is testing a combination of two targeted drugs (SI-B001 and SI-B003) plus chemotherapy as a first treatment for head and neck squamous cell carcinoma that has come back or spread to other parts of the body. The goal is to see if this combination works better than standard treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06678724Recruiting
Blood test study for head and neck cancer that has returned or spread
This trial is testing a new blood test (called a liquid biopsy) to better understand and predict the course of head and neck cancers that have come back or spread. If you join, researchers will use a special chip to look at your immune cells and tumor cells in your blood.
Zhubei, HsinChu CountyAges 20 years+ - NCT06682793RecruitingPhase 1/Phase 2
Study of A2B395 therapy for solid tumors with EGFR and HLA loss
This trial tests a new cell therapy called A2B395 for cancers that have EGFR, a protein on the cell surface, and have lost a specific marker called HLA-A*02. The therapy uses specially engineered immune cells to target and kill these cancer cells. This may help patients with colorectal, lung, head and neck, breast, kidney, or other solid tumors that are no longer responding to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06686342Recruiting
Drug sensitivity test for recurrent or metastatic head and neck cancer
This trial uses a patient's own tumor cells grown in a lab to test which drugs are most likely to work against their cancer. It aims to help guide treatment choices for people with head and neck cancer that has come back or spread.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06699212RecruitingPhase 3
Light-activated therapy with immunotherapy for head and neck cancer
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT07136545RecruitingPhase 1/Phase 2
HCB101 plus pembrolizumab for advanced head and neck cancer
This trial tests a new drug, HCB101, combined with the immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread and is no longer responding to platinum chemotherapy. The goal is to see if this combination can shrink tumors or slow cancer growth.
Taoyuan, Guishan DistrictAges 18 years+ - NCT06725368RecruitingPhase 2
Chemo plus cetuximab after pembrolizumab for head and neck cancer
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Ars-LaquenexyAges 18 years+ - NCT06736379RecruitingPhase 1
RNA Therapy Injections for Head and Neck Cancer
This trial tests a new type of immunotherapy made of self-amplifying RNA (saRNA) that produces a protein called IL-12. It's injected directly into head and neck tumors to help your immune system fight the cancer. The study is for people whose cancer has not responded well to standard treatments or who are having surgery to remove their tumor.
Stanford, CaliforniaAges 18 years+ - NCT06744296Recruiting
ctDNA surveillance for HPV-negative head and neck cancer
This trial uses a blood test to look for tiny bits of tumor DNA after treatment for head and neck cancer. It aims to see if this test can detect any remaining cancer cells early, so you and your doctor can make informed decisions.
Boston, MassachusettsAges 18 years+ - NCT06747390RecruitingPhase 1
Lidocaine injection before throat cancer surgery
This early-phase trial tests whether injecting lidocaine (a numbing medicine) into the tumor before surgery can help with pain or other outcomes in people with oropharyngeal cancer. It's for patients who are already scheduled for a scope procedure and surgery at the University of Pennsylvania.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+
Hear when a new Metastatic Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic head and neck squamous cell carcinoma?
- Yes. Clin2 currently lists 223 recruiting metastatic head and neck squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic head and neck squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic head and neck squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer Squamous Cell Carcinoma
- Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
- Resectable Head and Neck Squamous Cell Carcinoma
- Cutaneous Squamous Cell Carcinoma of the Head and Neck
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.